San Diego-based Mirati Therapeutics Inc. is a commercial-stage oncology company that has developed novel therapies to address the genetic and immunological promoters of cancer. Their pipeline is robust, with several drugs in various stages of development. The company's flagship product is KRAZATI, a targeted oral treatment for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. The company's other drug in clinical development, Sitravatinib, is a Phase 3 investigational spectrum-selective kinase inhibitor that inhibits receptor tyrosine kinases. This drug overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. Mirati's pipeline also includes MRTX1719, an investigational synthetic lethal PRMT5 inhibitor in clinical development, MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy when combined with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and MRTX1133, an investigational lead KRAS G12D compound. The company has a collaboration and license agreement with BeiGene Ltd. to develop, manufacture, and commercialize Sitravatinib and with Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. As more patients seek targeted cancer therapies, Mirati's novel approach to fighting cancer has put them at the forefront of the industry. The company, founded in 1995, has shown promise in its development of innovative therapies to treat cancer, and its growing pipeline suggests ongoing success in the future.
Mirati Therapeutics's ticker is MRTX
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 51-200 employees working at Mirati Therapeutics
It is mirati.com
Mirati Therapeutics is in the Healthcare sector
Mirati Therapeutics is in the Biotechnology industry
The following five companies are Mirati Therapeutics's industry peers: